Comparison of the effects of salmeterol and salbutamol on clinical activity and eosinophil cationic protein serum levels during the pollen season in atopic asthmatics

Lorenzo, Gabriele Di; Morici, Giuseppe; Norrito, F.; Mansueto, Pasquale; Melluso, M.; D’Ambrosio, Francesco Purello; Sangiorgi, G

doi:10.1111/j.1365-2222.1995.tb00397.x

Cited by 30 publications

(22 citation statements)

References 25 publications

(9 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Indeed, only serum EPX significantly decreased after 4 weeks of salmeterol treatment. A similar observation has been reported previously [23] for serum ECP using a short-term course of inhaled salmeterol. The authors ascribed the decrease in serum ECP to the inhibition of eosinophil degranulation.…”

Section: Discussionsupporting

confidence: 90%

See 1 more Smart Citation

Comparison of anti-inflammatory and clinical effects of beclomethasone dipropionate and salmeterol in moderate asthma

Bacci¹,

Franco²,

Bartoli³

et al. 2002

European Respiratory Journal

View full text Add to dashboard Cite

Inhaled corticosteroids and long-acting b 2 -agonists effectively control asthma symptoms and improve airway function. The effects of beclomethasone were compared with those of salmeterol on markers of eosinophilic inflammation in induced sputum in steroid-naïve asthmatic subjects with moderate asthma.Fifteen moderate asthmatics were treated with either beclomethasone dipropionate (500 mg b.i.d) or salmeterol (50 mg b.i.d) for 4 weeks, according to a randomised, double-blind, parallel-group study design. All patients underwent spirometry, methacholine test, sputum induction, and blood sampling before and after 2 and 4 weeks of treatment. They also recorded daily symptoms and peak expiratory flow (PEF).Sputum eosinophils, eosinophil cationic protein (ECP) and eosinophil protein X (EPX), and blood eosinophils, as well as the forced expiratory volume in one second (FEV1) and morning PEF, significantly improved after beclomethasone but not after salmeterol. PEF variability, the symptom score and rescue b 2 -agonist use significantly improved after both treatments, although the improvement in the symptom score tended to be greater after beclomethasone. After 2 and 4 weeks of beclomethasone treatment, both serum ECP and EPX decreased. With salmeterol, only serum EPX decreased, after 4 weeks. Bronchial hyperresponsiveness to methacholine did not change after either treatment.The authors conclude that beclomethasone, but not salmeterol, substantially improves airway inflammation in asthma. Beclomethasone also had an overall greater clinical effect, although the improvement in symptoms and peak expiratory flow variability was similar after both treatments. Eur Respir J 2002; 20: 66-72.

show abstract

Section: Discussionsupporting

confidence: 90%

“…Long-acting b 2 -agonists have been shown to have some anti-inflammatory effects in experimental models, including effects on sputum eosinophils [17] and blood ECP [23]. However, treatment with longacting b 2 -agonists as monotherapy for longer time periods has demonstrated marginal or no effects on airway inflammation [19,24,25].…”

Section: Discussionmentioning

confidence: 99%

Comparison of anti-inflammatory and clinical effects of beclomethasone dipropionate and salmeterol in moderate asthma

Bacci¹,

Franco²,

Bartoli³

et al. 2002

European Respiratory Journal

View full text Add to dashboard Cite

show abstract

“…The clinical superiority of long-acting over conventional short-acting β 2 -adrenoreceptor agonists has been suggested to be attributable in part to their possession of some anti-inflammatory actions [16, 22]. Ezeamuzie and al-Hage [16] reported that the differences in the anti-inflammatory actions of these agents reflected their differential ability to suppress the responses of activated granulocyte functions.…”

Section: Discussionmentioning

confidence: 99%

Differential Effects of Short-Acting β<sub>2</sub>-Agonists on Human Granulocyte Functions

Yasui¹,

Kobayashi²,

Yamazaki³

et al. 2005

Int Arch Allergy Immunol

View full text Add to dashboard Cite

Background: β₂-Adrenergic agonists play a pivotal role in the management of bronchial asthma. Although the major effect of short-acting β₂-agonists on the airway is relaxation of smooth muscles, they may also have several effects on surrounding immunomodulatory cells. Methods: We examined whether widely used short-acting β₂-agonists differ in their ability to modulate granulocyte functions, such as superoxide anion (O₂^–) production and degranulation. Results: Procaterol (PC), a full agonist, significantly inhibited both O₂^– production by granulocytes (neutrophils and eosinophils) and their degranulation at the clinically relevant concentrations, whereas salbutamol and tulobuterol (partial agonists) showed smaller effects. PC inhibited N-formyl methionyl-leucyl-phenylalanine-induced O₂^– production and peroxidase release, but failed to inhibit responses induced by phorbol 12-myristate 13-acetate and/or opsonized zymosan. Exposure to 5 × 10^–8M PC for 120 min resulted in approximately 50% inhibition of O₂^– production and degranulation of neutrophils. The effects of β₂-agonists were more obvious in neutrophils than in eosinophils. A selective β₂-receptor antagonist, ICI-118551, reversed the inhibitory effect of β₂-agonists (PC, salbutamol, tulobuterol B) on N-formyl methionyl-leucyl-phenylalanine-induced O₂^– production. Conclusions: These results suggest that β₂-agonists had an inhibitory effect on granulocyte functions, mainly mediated viareceptors and their efficacy. Our observations support that β₂-agonists with a rapid onset of action and high intrinsic efficacy (short-acting and full agonists) may be optimal for the rescue therapy against acute asthma attack and sedation of its airway inflammation in an early phase.

show abstract

“…In allergen-challenged asthmatic patients, pretreatment with salmeterol, a commonly used, long-acting b 2 agonist, has been reported to inhibit elevations in serum concentrations of eosinophil cationic protein (ECP) and eosinophil protein X (EPX) [28,29]. Furthermore, b 2 agonists have been shown to inhibit eosinophil function in vitro [28 , 30-32], and the anti-inflammatory effects of some b 2 agonists are mediated via b 2 receptors [32 , 33].…”

Section: Introductionmentioning

confidence: 99%

Inhibition by fenoterol of human eosinophil functions includingβ2-adrenoceptor-independent actions

Tachibana

Katô

Kimura

et al. 2002

Clinical and Experimental Immunology

View full text Add to dashboard Cite

SUMMARYAgonists at b 2 adrenoceptors are used widely as bronchodilators in treating bronchial asthma. These agents also may have important anti-inflammatory effects on eosinophils in asthma. We examined whether widely prescribed b 2 -adrenoceptor agonists differ in ability to suppress stimulus-induced eosinophil effector functions such as superoxide anion (O 2 -) generation and degranulation. To examine involvement of cellular adhesion in such responses, we also investigated effects of b 2 agonists on cellular adhesion and on CD11b expression by human eosinophils. O 2 -was measured using chemiluminescence. Eosinophil degranulation and adhesion were assessed by a radioimmunoassay for eosinophil protein X (EPX). CD11b expression was measured by flow cytometry. Fenoterol inhibited platelet-activating factor (PAF)-induced O 2 -generation by eosinophils significantly more than salbutamol or procaterol. Fenoterol partially inhibited PAF-induced degranulation by eosinophils similarly to salbutamol or procaterol. Fenoterol inhibited phorbol myristate acetate (PMA)-induced O 2 -generation and degranulation by eosinophils, while salbutamol or procaterol did not. Fenoterol inhibition of PMA-induced O 2 -generation was not reversed by ICI-118551, a selective b 2 -adrenoceptor antagonist. Fenoterol, but not salbutamol or procaterol, significantly inhibited PAF-induced eosinophil adhesion. Fenoterol inhibited O 2 -generation and degranulation more effectively than salbutamol or procaterol; these effects may include a component involving cellular adhesion. Inhibition also might include a component not mediated via b 2 adrenoceptors.

show abstract

Comparison of the effects of salmeterol and salbutamol on clinical activity and eosinophil cationic protein serum levels during the pollen season in atopic asthmatics

Cited by 30 publications

References 25 publications

Comparison of anti-inflammatory and clinical effects of beclomethasone dipropionate and salmeterol in moderate asthma

Comparison of anti-inflammatory and clinical effects of beclomethasone dipropionate and salmeterol in moderate asthma

Differential Effects of Short-Acting β<sub>2</sub>-Agonists on Human Granulocyte Functions

Inhibition by fenoterol of human eosinophil functions includingβ2-adrenoceptor-independent actions

Contact Info

Product

Resources

About